| 1 |
34709443 | [Surgical and interdisciplinary treatment of gastrointestinal stromal tumors]. | 2022 Jan |
1 |
| 2 |
34775854 | Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment. | 2022 Apr |
4 |
| 3 |
34983047 | KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. | 2022 |
1 |
| 4 |
35053574 | Introduction of Mutant GNAQ into Endothelial Cells Induces a Vascular Malformation Phenotype with Therapeutic Response to Imatinib. | 2022 Jan 14 |
2 |
| 5 |
35120552 | GnRH antagonist weakens endometrial stromal cells growth ability by decreasing c-kit receptor expression. | 2022 Feb 4 |
1 |
| 6 |
35174150 | Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor. | 2022 |
1 |
| 7 |
35194937 | Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours. | 2022 Apr |
1 |
| 8 |
35217782 | New treatment strategies for advanced-stage gastrointestinal stromal tumours. | 2022 May |
2 |
| 9 |
35349049 | Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs? | 2022 May |
1 |
| 10 |
35487307 | Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet? | 2022 Jun |
1 |
| 11 |
35585158 | Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability. | 2022 May 18 |
2 |
| 12 |
33030616 | Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways. | 2021 Mar |
1 |
| 13 |
33247506 | c-KIT-ERK1/2 signaling activated ELK1 and upregulated carcinoembryonic antigen expression to promote colorectal cancer progression. | 2021 Feb |
1 |
| 14 |
33307872 | New insights into the clinical management of advanced gastrointestinal stromal tumors. | 2021 Mar |
2 |
| 15 |
33389076 | A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth. | 2021 Apr |
1 |
| 16 |
33402214 | The management of metastatic GIST: current standard and investigational therapeutics. | 2021 Jan 5 |
1 |
| 17 |
33422470 | A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. | 2021 Feb |
1 |
| 18 |
33524167 | Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. | 2021 Apr 1 |
1 |
| 19 |
33641024 | Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time? | 2021 Feb 27 |
2 |
| 20 |
33670651 | Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors. | 2021 Feb 18 |
1 |
| 21 |
33673554 | Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. | 2021 Feb 27 |
2 |
| 22 |
33727226 | Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. | 2021 May 1 |
4 |
| 23 |
33737510 | Gastrointestinal stromal tumours. | 2021 Mar 18 |
2 |
| 24 |
33743084 | Surgical Management of Metastatic Gastrointestinal Stromal Tumors. | 2021 Mar 20 |
1 |
| 25 |
33783002 | Thymoquinone chemosensitizes human colorectal cancer cells to imatinib via uptake/efflux genes modulation. | 2021 Jun |
2 |
| 26 |
33848847 | G-CSF promotes alloregulatory function of MDSCs through a c-Kit dependent mechanism. | 2021 Jun |
1 |
| 27 |
33947686 | Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis. | 2021 Jul |
1 |
| 28 |
34065883 | Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. | 2021 May 12 |
1 |
| 29 |
34089444 | Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. | 2021 Jul |
1 |
| 30 |
34236401 | Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. | 2021 Sep 1 |
1 |
| 31 |
34298737 | Immunotherapy Strategies for Gastrointestinal Stromal Tumor. | 2021 Jul 14 |
1 |
| 32 |
34322383 | Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. | 2021 |
1 |
| 33 |
34324512 | Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors. | 2021 |
1 |
| 34 |
34359600 | Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. | 2021 Jul 23 |
4 |
| 35 |
34376580 | KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. | 2021 Oct |
2 |
| 36 |
34398495 | Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls. | 2021 Dec |
1 |
| 37 |
34446510 | Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation. | 2021 Aug 26 |
1 |
| 38 |
34489967 | Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. | 2021 |
1 |
| 39 |
34589354 | Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy. | 2021 Aug |
2 |
| 40 |
34621020 | E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. | 2021 Dec |
1 |
| 41 |
34889232 | Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol. | 2021 Dec 10 |
2 |
| 42 |
34917498 | Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib. | 2021 |
1 |
| 43 |
34944576 | Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. | 2021 Nov 24 |
2 |
| 44 |
31197522 | Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors. | 2020 Jan |
1 |
| 45 |
31702819 | Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature. | 2020 Apr |
1 |
| 46 |
31758409 | Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). | 2020 Jan |
1 |
| 47 |
31776458 | Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. | 2020 Feb |
2 |
| 48 |
31892598 | Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece. | 2020 Jan |
1 |
| 49 |
32005261 | ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report. | 2020 Jan 31 |
1 |
| 50 |
32082541 | Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib. | 2020 |
4 |